Catalyst overview
Research summary
This catalyst tracks a Phase 1 data readout for STK-002 in Autosomal Dominant Optic Atrophy (ADOA). The expected timing is based on the latest available company guidance and may change.
OSPREY study. 8/12/25- Trial now underway. 10/20/25- Presented two-year data from FALCON study at AAO'25. 11/4/25- Activate EU sites in early 2026. 08/03/26:- OSPREY cohort 1 dosing complete; cohort 2 starts August 2026, Ph1 data H1 2027.
Verification
Confirm timing and program details against the company announcement or filing.